Extended Data Fig. 2: Visugromab in combination with nivolumab induces remissions in a fraction of anti-PD-1/-L1 relapsed/refractory last-line NSCLC and urothelial cancer. | Nature

Extended Data Fig. 2: Visugromab in combination with nivolumab induces remissions in a fraction of anti-PD-1/-L1 relapsed/refractory last-line NSCLC and urothelial cancer.

From: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Extended Data Fig. 2: Visugromab in combination with nivolumab induces remissions in a fraction of anti-PD-1/-L1 relapsed/refractory last-line NSCLC and urothelial cancer.

(a, b) Spider plots of NSCLC (a) and UC (b) patients illustrating changes in tumour size, response assessment was done according to investigator-assessed RECIST1.1, and time on study. Patients with partial or complete response (PR and CR) are highlighted in light and dark green respectively, arrow indicates ongoing treatment.

Source Data

Back to article page